Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73598968" target="_blank" >RIV/61989592:15110/19:73598968 - isvavai.cz</a>
Result on the web
<a href="https://journals.lww.com/co-neurology/fulltext/2019/06000/Current_therapeutic_landscape_in_multiple.9.aspx" target="_blank" >https://journals.lww.com/co-neurology/fulltext/2019/06000/Current_therapeutic_landscape_in_multiple.9.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/WCO.0000000000000700" target="_blank" >10.1097/WCO.0000000000000700</a>
Alternative languages
Result language
angličtina
Original language name
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
Original language description
Purpose of review To critically assess the current landscape of disease-modifying agents for multiple sclerosis ( MS). Treatment algorithms will be discussed and studies for new agents in late development or recently approved are analyzed in terms of their impact on current treatment strategies. Recent findings A real-world study from Wales suggests that early initiation of highly effective therapy may provide more benefit that an escalation approach in relapsing MS. A study from the MSBase dataset found evidence that early treatment with highly effective therapies decreased the risk of developing secondary progressive MS. Ocrelizumab is highly efficacious in relapsing MS and in a group of patients with primary progressive MS. Another CD20 directed mAb, ofatumumab, is in phase 3. A large study examining extended interval dosing of natalizumab in an attempt to decrease the risk of developing progressive multifocal leukoencephalopathy is underway. Cladribine and alemtuzumab may work by immune reconstitution. Siponimod was recently approved by United States Federal Drug Administration for relapsing MS and active secondary progressive MS. Other S1P receptor modulators are being studied in phase 3 trials for relapsing MS. Cladribine received FDA approval as treatment for relapsing and active secondary progressive MS. Autologous hematopoetic stem-cell transplantation may be an option for treatment-refractory MS.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CURRENT OPINION IN NEUROLOGY
ISSN
1350-7540
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
365-377
UT code for WoS article
000480723400008
EID of the result in the Scopus database
2-s2.0-85065348368